Standard Tuberculosis Treatment Guidelines

Drug-Susceptible TB Treatment

The American Thoracic Society recommends a four-drug regimen of isoniazid, rifampin, pyrazinamide, and ethambutol for 2 months, followed by isoniazid and rifampin for 4 months for drug-susceptible TB 1, 2
Ethambutol can be discontinued once drug susceptibility confirms full susceptibility to isoniazid and rifampin, particularly if the patient has low risk for drug resistance 1, 2
The total treatment duration is 6 months for most patients with drug-susceptible pulmonary TB 1

For MDR-TB, use at least five effective drugs in the intensive phase, prioritizing newer oral agents over injectable agents 3, 4, 5
The American Thoracic Society strongly recommends later-generation fluoroquinolone and bedaquiline in every MDR-TB regimen unless contraindicated 4, 5
Continue the intensive phase for 5-7 months after culture conversion 4, 5
The total MDR-TB treatment duration is 15-21 months after culture conversion for standard MDR-TB, and 15-24 months for pre-XDR-TB and XDR-TB 4, 5

Children should receive appropriately adjusted doses of isoniazid, rifampin, pyrazinamide, and ethambutol 1
Pyridoxine (vitamin B6) 25-50 mg daily should be administered to all HIV-infected patients receiving isoniazid to prevent neurological side effects 2
For HIV-positive patients receiving protease inhibitors or NNRTIs, substitute rifabutin for rifampin with appropriate dose adjustments 2

Hepatotoxicity monitoring is essential, especially during the first 2 months 2
Monitor for optic neuritis with ethambutol, and for tendinopathy, peripheral neuropathy, and QTc prolongation with levofloxacin 6
Be aware of extensive drug interactions with oral contraceptives, anticoagulants, and antiretroviral drugs requiring dose adjustments with rifampin 2